Intercept Pharmaceuticals, Inc. ICPT NASDAQ

Intercept Pharmaceuticals, Inc. (ICPT) generated $-26.78M in operating cash flow for fiscal year 2022. After capital expenditures of $568K, free cash flow was $-27.35M.

Free cash flow margin was -9.6% of revenue. Cash conversion ratio was 0.15x, suggesting some earnings are non-cash.

The company returned $557K in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (33/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (60/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (100/100) — Cash conversion ratio was 0.15x suggests some earnings are non-cash items

Overall SharesGrow Score: 62/100 with 3/7 criteria passed.